Semaglutide, the active ingredient in weight-loss drugs such as Ozempic and Wegovy, has been found to potentially slow down the aging process by reducing inflammation, according to studies presented at the European Society of Cardiology conference. The drug, initially marketed as a diabetes treatment, was shown to have broad benefits in improving cardiometabolic health, leading to speculation that it could have anti-aging effects.
The Select trial, which tracked 17,604 adults aged 45 years or older over up to five years, found that participants who took the drug had a lower rate of death from all causes. This has led experts to suggest that semaglutide could be used to treat conditions linked to inflammation, such as cancer, Alzheimer's, and Parkinson's.
However, weight-loss drugs like Ozempic come with potential risks, including severe side effects like vomiting, diarrhea, and stomach pain. Some physicians have warned against buying and taking these drugs without medical supervision, citing dangerous complications such as pancreatitis and electrolyte imbalances.
National Health Service (NHS) England medical director Stephen Powis has cautioned against using weight-loss drugs as a "quick fix" for achieving a "beach body," emphasizing the importance of medical supervision in their use. While these drugs may be a powerful tool in combating obesity, it is crucial to use them responsibly to avoid complications and harmful consequences.
Overall, the potential anti-aging benefits of semaglutide in weight-loss drugs like Ozempic and Wegovy are promising, but it is essential to weigh the risks and benefits carefully and consult with a healthcare provider before starting any weight-loss medication regimen.